Patents by Inventor Tamar Ben-Yedidia
Tamar Ben-Yedidia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9353159Abstract: An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is B(X1ZX2Z . . . Xm)nB or B(X1)nZ(X2)nZ . . . (Xm)nB; wherein B is an optional sequence of 1-4 amino acid residues; n is at each occurrence independently an integer of 2-50; m is an integer of 3-15; each of X1, X2 . . . Xm is an influenza peptide epitope of 4-24 amino acid residues; and Z at each occurrence is a bond or a spacer of 1-4 amino acid residues.Type: GrantFiled: April 28, 2014Date of Patent: May 31, 2016Assignee: BiondVax Pharmaceuticals Ltd.Inventors: Tamar Ben-Yedidia, Yossi Singer
-
Patent number: 9303070Abstract: The present invention relates to use of multimeric multi-epitope peptide-based compositions for immunizing subjects against influenza by administering the compositions to the subject prior to or together with seasonal or pandemic influenza vaccines. The present invention also relates to compositions that include a multimeric multi-epitope polypeptide and a seasonal or pandemic preparation against influenza.Type: GrantFiled: February 22, 2011Date of Patent: April 5, 2016Assignee: BiondVax Pharmaceuticals Ltd.Inventors: Tamar Ben-Yedidia, George H. Lowell
-
Patent number: 9029526Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.Type: GrantFiled: November 19, 2012Date of Patent: May 12, 2015Assignee: Yeda Research and Development Co. Ltd.Inventors: Ruth Arnon, Sung-Ho Jeon, Basak Kayhan, Tamar Ben-Yedidia
-
Publication number: 20140286982Abstract: An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is B(X1ZX2Z . . . Xm)nB or B(X1)nZ(X2)nZ . . . (Xm)nB; wherein B is an optional sequence of 1-4 amino acid residues; n is at each occurrence independently an integer of 2-50; m is an integer of 3-15; each of X1, X2 . . . Xm is an influenza peptide epitope of 4-24 amino acid residues; and Z at each occurrence is a bond or a spacer of 1-4 amino acid residues.Type: ApplicationFiled: April 28, 2014Publication date: September 25, 2014Applicant: BIONDVAX PHARMACEUTICALS LTD.Inventors: Tamar BEN-YEDIDIA, Yossi SINGER
-
Publication number: 20140227306Abstract: The present invention relates to use of multimeric multi-epitope peptide-based compositions for immunizing subjects against influenza by administering the compositions to the subject prior to or together with seasonal or pandemic influenza vaccines. The present invention also relates to compositions that include a multimeric multi-epitope polypeptide and a seasonal or pandemic preparation against influenza.Type: ApplicationFiled: February 22, 2011Publication date: August 14, 2014Applicant: BIONDVAX PHARMACEUTICALS Ltd.Inventors: Tamar Ben-Yedidia, George H. Lowell
-
Patent number: 8747861Abstract: The present invention relates to multimeric multi-epitope peptide-based vaccines. In particular, the present invention relates to the use of multimeric multi-epitope peptide-based vaccines eliciting protective immunity to influenza.Type: GrantFiled: August 3, 2008Date of Patent: June 10, 2014Assignee: BiondVax Pharmaceuticals Ltd.Inventors: Tamar Ben-Yedidia, Yossi Singer
-
Patent number: 8357789Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.Type: GrantFiled: September 18, 2009Date of Patent: January 22, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Ruth Arnon, Sung-Ho Jeon, Basak Kayhan, Tamar Ben-Yedidia
-
Publication number: 20110182974Abstract: The present invention relates to multimeric multi-epitope peptide-based vaccines. In particular, the present invention relates to the use of multimeric multi-epitope peptide-based vaccines eliciting protective immunity to influenza.Type: ApplicationFiled: August 3, 2008Publication date: July 28, 2011Inventors: Tamar Ben-Yedidia, Yossi Singer
-
Patent number: 7914797Abstract: The present invention relates to influenza vaccines for human and veterinary use. In particular, the present invention provides a vaccine able to effect long term and cross-strain protection by including at least two influenza virus epitopes expressed as a chimeric polypeptide wherein at least one epitope is influenza A virus matrix protein epitope and the second epitope is a haemagglutinin peptide epitope.Type: GrantFiled: December 6, 2006Date of Patent: March 29, 2011Assignee: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Ruth Arnon, Tamar Ben-Yedidia
-
Patent number: 7786279Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.Type: GrantFiled: February 24, 2004Date of Patent: August 31, 2010Assignee: Yeda Research And Development Co. Ltd.Inventors: Ruth Arnon, Sung-Ho Jeon, Basak Kayhan, Tamar Ben-Yedidia
-
Publication number: 20100021489Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.Type: ApplicationFiled: September 18, 2009Publication date: January 28, 2010Applicant: Yeda Research And Development Co. Ltd.Inventors: Ruth Arnon, Sung-Ho Jeon, Basak Kayhan, Tamar Ben-Yedidia
-
Publication number: 20090304730Abstract: The present invention relates to influenza vaccines for human and veterinary use. In particular, the present invention provides a vaccine able to effect long term and cross-strain protection by including at least two influenza virus epitopes expressed as a chimeric polypeptide wherein at least one epitope is influenza A virus matrix protein epitope and the second epitope is a haemagglutinin peptide epitope.Type: ApplicationFiled: December 6, 2006Publication date: December 10, 2009Inventors: Ruth Arnon, Tamar Ben-Yedidia
-
Patent number: 7514086Abstract: A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii) one T-helper hemagglutinin (HA) or nucleo-protein (NP) epitope that can bind to many HLA molecules; and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that are restricted to the most prevalent HLA molecules in different human populations.Type: GrantFiled: February 7, 2007Date of Patent: April 7, 2009Assignee: Yeda Research and Development, Co. LtdInventors: Ruth Arnon, Tamar Ben-Yedidia, Raphael Levi
-
Publication number: 20070122424Abstract: A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii) one T-helper hemagglutinin (HA) or nucleo-protein (NP) epitope that can bind to many HLA molecules; and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that are restricted to the most prevalent HLA molecules in different human populations.Type: ApplicationFiled: February 7, 2007Publication date: May 31, 2007Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Ruth Arnon, Tamar Ben-Yedidia, Raphael Levi
-
Patent number: 7192595Abstract: A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii) one T-helper hemagglutinin (HA) or nucleo-protein (NP) epitope that can bind to many HLA molecules; and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that are restricted to the most prevalent HLA molecules in different human populations.Type: GrantFiled: May 17, 2004Date of Patent: March 20, 2007Assignee: Yeda Research and Development Co. Ltd.Inventors: Ruth Arnon, Tamar Ben-Yedidia, Raphael Levi
-
Publication number: 20070059806Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.Type: ApplicationFiled: February 24, 2004Publication date: March 15, 2007Applicant: Yeda Research and Development Co., Ltd. at the Weizmann Institute of ScienceInventors: Ruth Arnon, Sung-Ho Jeon, Basak Kayhan, Tamar Ben-Yedidia
-
Publication number: 20050002954Abstract: A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii) one T-helper hemagglutinin (HA) or nucleo-protein (NP) epitope that can bind to many HLA molecules; and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that are restricted to the most prevalent HLA molecules in different human populations.Type: ApplicationFiled: May 17, 2004Publication date: January 6, 2005Inventors: Ruth Arnon, Tamar Ben-Yedidia, Raphael Levi
-
Patent number: 6740325Abstract: A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii) one T-helper hemagglutinin (HA) or nucleo-protein (NP) epitope that can bind to many HLA molecules; and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that are restricted to the most prevalent HLA molecules in different human populations.Type: GrantFiled: July 30, 2001Date of Patent: May 25, 2004Assignee: Yeda Research and Development Co. Ltd.Inventors: Ruth Arnon, Tamar Ben-Yedidia, Raphael Levi